Lenalidomide: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='4tz4' size='340' side='right' caption='Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide ([[4tz4]])' scene='95/954025/Cv/2'> | <StructureSection load='4tz4' size='340' side='right' caption='Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide ([[4tz4]])' scene='95/954025/Cv/2'> | ||
<scene name='95/954025/Cv/4'>Lenalidomide</scene>, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). See also [https://en.wikipedia.org/wiki/Lenalidomide]. | <scene name='95/954025/Cv/4'>Lenalidomide</scene>, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). See also [https://en.wikipedia.org/wiki/Lenalidomide Lenalidomide]. | ||
On a molecular level, <scene name='95/954025/Cv/3'>lenalidomide has been shown to interact with the ubiquitin E3 ligase cereblon</scene> and target this enzyme to degrade the Ikaros transcription factors IKZF1 and IKZF3. <scene name='95/954025/Cv/5'>Lenalidomide binding site</scene>. | On a molecular level, <scene name='95/954025/Cv/3'>lenalidomide has been shown to interact with the ubiquitin E3 ligase cereblon</scene> and target this enzyme to degrade the Ikaros transcription factors IKZF1 and IKZF3. <scene name='95/954025/Cv/5'>Lenalidomide binding site</scene>. | ||